跳至主要内容
临床试验/NL-OMON41809
NL-OMON41809已完成不适用

Stratifying Risk in Barrett*s Esophagus: A Pilot Study for Biomarker-Based Patient Management - ASGE Biomarkers Study

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1) Able to read, comprehend, and complete the consent form.
  • 2) Aged 18 to 80.
  • 3) Diagnosed with at least 3 centimeters (>3cm) of Barrett*s esophagus AND no dysplasia or low grade dysplasia per review by pathologist.

排除标准

  • 1) Pregnant women.
  • 2) Current use of blood thinners such as coumadin, warfarin, heparin and/or low molecular weight heparin (requires discontinuation of medication 5 days prior to and 6 days after EGD).
  • 3) Known bleeding disorder.
  • 4) Status post partial or complete esophageal resection.
  • 5) Current or past diagnosis of invasive esophageal cancer (previous intramucosal cancer is allowable, if removed by endoscopic mucosal resection with histologically confirmed negative lateral and deep margins).
  • 6) Prior ablative therapy of the esophagus including prior radiofrequency ablation (RFA), photodynamic therapy (PDT), spray cryotherapy, and other ablation therapies. Prior endoscopic mucosal resection (EMR) is acceptable.

研究者

相似试验

Stratifying Risk in Barrett*s Esophagus: A Pilot... | 临床试验